A new HIV drug, Lenacapavir, represents a major breakthrough in prevention and treatment, with the potential to significantly reduce transmission. Yet for many of the populations most affected by HIV, access remains out of reach due to high costs, patent protections, and limited distribution. The gap between innovation and access demonstrates how advances in medicine do not automatically translate into real-world impact. In global health, who benefits from new treatments is often shaped less by need and more by structural barriers. When life-saving interventions exist but remain inaccessible, progress becomes uneven by design. Read more here.